Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer.
Ontology highlight
ABSTRACT: The cost and time to develop a drug continues to be a major barrier to widespread distribution of medication. Although the genomic revolution appears to have had little impact on this problem, and might even have exacerbated it because of the flood of additional and usually ineffective leads, the emergence of high throughput resources promises the possibility of rapid, reliable and systematic identification of approved drugs for originally unintended uses. In this paper we develop and apply a method for identifying such repositioned drug candidates against breast cancer, myelogenous leukemia and prostate cancer by looking for inverse correlations between the most perturbed gene expression levels in human cancer tissue and the most perturbed expression levels induced by bioactive compounds.
SUBMITTER: Shigemizu D
PROVIDER: S-EPMC3276504 | biostudies-literature | 2012 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA